These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10865602)

  • 1. Vancomycin peak serum concentration monitoring.
    Tam VH; Moore GE; Triller DM; Briceland LL
    J Intraven Nurs; 1999; 22(6):336-42. PubMed ID: 10865602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimal vancomycin serum level in Staphylococcus aureus infections?].
    Bingen E; Mariani-Kurkdjian P; Nebbad B
    Med Mal Infect; 2006 Sep; 36(9):439-42. PubMed ID: 17027219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic and anti-infective agent use and administration in homecare.
    Barrio DJ
    J Intraven Nurs; 1998; 21(1):50-8. PubMed ID: 9515482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent aspects of monitoring the dosage of aminoglycosides and vancomycin].
    Cheymol G; Poirier JM
    Bull Acad Natl Med; 1998; 182(2):285-97; discussion 297-8. PubMed ID: 9648344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of resistant gram-positive infection: value of glycopeptide antibiotics vancomycin and teicoplanin].
    Waldvogel F
    Schweiz Med Wochenschr; 1993 Dec; 123(50):2353-6. PubMed ID: 8272810
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare reimbursement for home infusion therapy: a contributor to the development of community acquired vancomycin-resistant enterococci?
    Herbert JR
    J Intraven Nurs; 1996; 19(2):99-101. PubMed ID: 8852170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function.
    Khotaei GT; Jam S; SeyedAlinaghi S; Motamed F; Nejat F; Taghi M; Ashtiani H; Izadyar M
    Acta Med Iran; 2010; 48(2):91-4. PubMed ID: 21133000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection.
    Kondo M; Nakagawa S; Orii S; Itohara K; Sugimoto M; Omura T; Sato Y; Imai S; Yonezawa A; Nakagawa T; Matsubara K
    Biol Pharm Bull; 2020; 43(10):1463-1468. PubMed ID: 32999156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of vancomycin in adult cancer patients.
    Al-Kofide H; Zaghloul I; Al-Naim L
    J Oncol Pharm Pract; 2010 Dec; 16(4):245-50. PubMed ID: 20015925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance.
    Nicas TI; Zeckel ML; Braun DK
    Trends Microbiol; 1997 Jun; 5(6):240-9. PubMed ID: 9211645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid.
    French G
    Int J Clin Pract; 2001; 55(1):59-63. PubMed ID: 11219321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are serum levels of vancomycin useful in the first week of therapy?
    Goldstein E; Bartholomew WR; Vickers MK; Parr T
    Mo Med; 1995 Sep; 92(9):596-9. PubMed ID: 7476836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Improvement of bactericide activity in hospital treatment of gram positive infections].
    Aguilar L; Barberán J; Prieto J; Giménez M
    Rev Esp Quimioter; 2008 Mar; 21(1):37-44. PubMed ID: 18443932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taking i.v. therapy into the community.
    Zeier L
    Nurs N Z; 1998 Nov; 4(10):14-5. PubMed ID: 10586762
    [No Abstract]   [Full Text] [Related]  

  • 18. Limitations of vancomycin in the management of resistant staphylococcal infections.
    Kollef MH
    Clin Infect Dis; 2007 Sep; 45 Suppl 3():S191-5. PubMed ID: 17712746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
    Jones RN
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. For nosocomial vancomycin-resistant enterococcal infections: the ounce of prevention or the pound of cure?
    Farr BM
    Clin Infect Dis; 2004 Apr; 38(8):1116-8. PubMed ID: 15095216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.